“Stated interest expense for the three and six months ended June 30, 2026 increased from the comparable periods in 2025 primarily due to the increase in the average principal amount of our outstanding debt.”10-Q · Jul 29, 2026 ↗
Ares Capital Corporation
ARCC
Market read
Ares Capital Corporation's move is spreading beyond its market group.
ARCC accounts for 9.7% of the group's measured movement across 7.6 effective names. raw member direction is mixed; 7 of 12 SPY-adjusted paths align to the downside. Capital-flow agreement is 15%, so confirmation is not yet clean. No verified headline preceded the measured group move.
Is this move genuinely shared?
BXSL, ARES, ABBV moved materially before ARCC. ARCC crossed its material path threshold at 14:05 ET, 165 minutes after the first measured mover. BMY followed.
5 of 25 members in Biopharmaceuticals and Care are active. 0 of 5 disclosed connections are confirming.
- At least 17 of 25 durable members become active together.
- Capital-flow agreement rises above 55%.
- BDX remains aligned with the group in the next market snapshot.
Invalidation: The live read weakens if participation falls to 8 of 25 members or fewer.
Research brief
The story so far
ARCC accounts for 9.7% of the group's measured movement across 7.6 effective names. raw member direction is mixed; 7 of 12 SPY-adjusted paths align to the downside. Capital-flow agreement is 15%, so confirmation is not yet clean. No verified headline preceded the measured group move.
No thresholded supportive filing evidence is available yet.
No thresholded adverse filing evidence is available yet.
- At least 17 of 25 durable members become active together.
- Capital-flow agreement rises above 55%.
- BDX remains aligned with the group in the next market snapshot.
Company research
Understand the business, not just the ticker
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
- Credit and interest rates has repeated favorable evidence across 5 filings.
No qualifying adverse evidence was identified; that is not proof there is no downside.
No credible peer-relative valuation comparison is available yet.
Price as of Sep 10, 2026
19.67What management says matters
Persistent and emerging business drivers
“These tailwinds were partially offset by increased uncertainty related to geopolitical developments, with markets now expecting the Federal Reserve to maintain policy rates at current levels this year amid rising near-term inflation expectations.”10-Q · Apr 28, 2026 ↗
“These tailwinds were partially offset by slower job growth and increased uncertainty related to tariff policies and risks from various geopolitical developments.”10-K · Feb 4, 2026 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales — · EV/sales —. Comparisons use only industry-matched filing peers.
Scenarios are withheld for Financial Services until sector-specific earnings and capital metrics are available; generic revenue/P/S scaffolds would be misleading.
Price action
How the market is pricing the story
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for ARCC. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for ARCC. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind ARCC
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depended on by
ADMAADMA Biologics, Inc.lenderFeb 25, 2026 ▾
“Ares Credit Agreement On December 18, 2023 (the “Ares Closing Date”), we entered into a senior secured credit facility (the “Ares Credit Agreement”) with Ares Capital Corporation and certain credit funds affiliated with Ares Capital Corporation (collectively,…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 4 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
ARCC is currently a Participant in the organic co-movement group Biopharmaceuticals and Care. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 1 filing-linked name are in the relationship map; none is currently confirmed as moving with the group.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.